Candida-associated denture stomatitis is the most common form of oral candidal infection, with Candida albicans being the principal etiological agent. Candida adheres directly or via an intermediary layer of plaque-forming bacteria to denture acrylic. Despite antifungal therapy to treat denture stomatitis, infection is reestablished soon after the treatment ceases. In addition, many predisposing factors have been identified as important in the development of oral candidiasis, including malnourishment, common endocrine disorders, such as diabetis mellitus, antibacterial drug therapy, corticosteroids, radiotherapy and other immunocompromised conditions, such as acquired immunodeficiency syndrome (AIDS). These often results in increased tolerance to the most commonly used antifungals. So this review suggests new therapies to oral candidiasis.
INTRODUCTION
Candida species are commensal yeast in healthy humans and may cause systemic infections under immunocompromised situations due to its high adaptability to different host niches by the activation of appropriate sets of genes in response to complex environmental signals (1) .
Denture stomatitis, also known as atrophic candidiasis, is the most common fungal infection in elder patients and in those who wear dentures. It is the result of a poor denture cleanliness, poor oral hygiene and wearing denture at night, which causes a decrease in the salivary flow below denture surface, thus facilitating the accumulation of characteristic biofilms (48) .
Terai and Shimahara (51) have isolated species of
Candida in the oral cavity and they found that the frequency does not necessarily imply disease in many healthy people without clinical manifestation, it just reflects that they may be carriers of Candida, with no infections.
Many predisposing factors have been identified as important in the development of oral candidiasis, including malnourishment, common endocrine disorders, such as diabetes mellitus, antibacterial drug therapy, corticosteroids, radiotherapy and other immunocompromised conditions, such as acquired immunodeficiency syndrome (AIDS) (49) .
Candida albicans is the most common species of yeasts isolated from patients with these predisposing factors (19) and non-albicans species have been isolated from the oral cavity of 825 Anibal 
Forms of Oral Candidiasis and Conventional Therapies
Candida-associated denture stomatitis is the most common form of oral candidal infection (56), with Candida albicans being the main etiological agent (34) . At least 65% of elderly denture-wearers carry Candida, and these yeasts have been isolated from 93% of patients with denture stomatitis. Candida adheres directly or via an intermediary layer of plaque-forming bacteria to denture acrylic (polymethylmethacrylate) (15) .
Despite antifungal therapy to treat denture stomatitis, infection is reestablished soon after the treatment ceases, suggesting that denture plaque may serve as a protected reservoir for C.
albicans. Although multiple factors are likely to contribute to the development of denture stomatitis, it unequivocally involves denture plaque (12) .
Since the 1980s, the imidazoles became increasingly more popular and seem to have replaced, to a large extent, the polyenes for the treatment of oral thrush. Miconazole and ketoconazole were found to be effective in in vitro denture liners, but they are more expensive and the toxicity of ketoconazole is a problem (44) . Rapid relapse (7, 11) Candida albicans cells resuspended from a mature biofilm maintained fluconazole resistance even after the biofilm had been disrupted (45) . Treatment methods directed towards reducing initial fungal attachment and subsequent biofilm development on denture acrylic would be beneficial in reducing the incidence and severity of this condition (43) .
Exposure of Candida to chlorhexidine results in loss of structural integrity, less ability to adhere, and fragmentation of the cell wall (28) . A notable feature of chlorhexidine is that it Anibal, P.C. et al. Antifungal therapies to oral candidiasis adheres to salivary glycoproteins in plaque and is slowly released over time. Following a 1 min rinse with chlorhexidine, 30% was retained in the oral cavity for 24h (8) . This pharmacologic feature of chlorhexidine permits extended activity following exposure in the oral environment and allows a wide spacing of doses (43) .
Resistance in Immunocompromised Patients
Powderly et al. (42) For Nakamura and Takahashi (32), C. parapsilosis was the major fungi isolated from hospitalized patients in Japan, followed by C. albicans and all of those isolates were susceptible to fluconazole. Fluconazole has been frequently used due to its lower toxicity compared to amphotericin B.
Viscoli (54) stated that fluconazole is effective and less toxic than amphotericin B. According to these authors, resistance to fluconazole is not very common in short treatments, however in immunocompromised patients under long-term therapy, the substitution of susceptible species by naturally resistant ones is observed. The increasing incidence of fungal infections and widespread use of the newer oral triazoles have led to a resurgence of interest in antifungal resistance for these agents.
Mechanism of Action of the Antifungal Drugs
Polyenes albicans and S. cerevisiae (36) .
Development of Resistance
The chronic use of azole compounds in the prevention of systemic mycosis, especially in patients with HIV infection, allows the selection of resistant isolated to this therapy (35) . 
New Antimicrobial Therapies
Due to the increasing resistance of microorganisms to antibiotics administrated, which no longer fully meet the medical necessity with respect to spectrum, potency, safety and pharmacokinetic properties, increasing the incidence of properties that is being studied by diverse researchers, but many of these compounds are not known yet. The investigation of these active principles, once they have different targets that were found in the antifungal in use, is a potential area that must be studied.
